Literature DB >> 31292196

The Role of the EGF Receptor in Sex Differences in Kidney Injury.

Ming-Zhi Zhang1,2, Kensuke Sasaki3,2, Yan Li3, Zhilian Li3, Yu Pan3,2, Guan-Nan Jin3,2, Yinqiu Wang3,2, Aolei Niu3,2, Suwan Wang3,2, Xiaofeng Fan3,2, Jian Chun Chen3,2, Corina Borza3,2, Haichun Yang4, Ambra Pozzi3,2, Agnes B Fogo2,4, Raymond C Harris1,2,5.   

Abstract

BACKGROUND: Sex differences mediating predisposition to kidney injury are well known, with evidence indicating lower CKD incidence rates and slower decline in renal function in nondiabetic CKD for premenopausal women compared with men. However, signaling pathways involved have not been elucidated to date. The EGF receptor (EGFR) is widely expressed in the kidney in glomeruli and tubules, and persistent and dysregulated EGFR activation mediates progressive renal injury.
METHODS: To investigate the sex differences in response to renal injury, we examined EGFR expression in mice, in human kidney tissue, and in cultured cell lines.
RESULTS: In wild type mice, renal mRNA and protein EGFR levels were comparable in males and females at postnatal day 7 but were significantly lower in age-matched adult females than in adult males. Similar gender differences in renal EGFR expression were detected in normal adult human kidneys. In Dsk5 mutant mice with a gain-of-function allele that increases basal EGFR kinase activity, males had progressive glomerulopathy, albuminuria, loss of podocytes, and tubulointerstitial fibrosis, but female Dsk5 mice had minimal kidney injury. Oophorectomy had no effect on renal EGFR levels in female Dsk5 mice, while castration protected against the kidney injury in male Dsk5 mice, in association with a reduction in EGFR expression to levels seen in females. Conversely, testosterone increased EGFR expression and renal injury in female Dsk5 mice. Testosterone directly stimulated EGFR expression in cultured kidney cells.
CONCLUSIONS: These studies indicate that differential renal EGFR expression plays a role in the sex differences in susceptibility to progressive kidney injury that may be mediated at least in part by testosterone.
Copyright © 2019 by the American Society of Nephrology.

Entities:  

Keywords:  DSK5; EGFR; glomerulosclerosis; testosterone; tubulointerstitial fibrosis

Mesh:

Substances:

Year:  2019        PMID: 31292196      PMCID: PMC6727256          DOI: 10.1681/ASN.2018121244

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  43 in total

Review 1.  Ligand-induced, receptor-mediated dimerization and activation of EGF receptor.

Authors:  Joseph Schlessinger
Journal:  Cell       Date:  2002-09-20       Impact factor: 41.582

2.  Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach.

Authors:  Alexandre Lautrette; Shunqiang Li; Rohia Alili; Susan W Sunnarborg; Martine Burtin; David C Lee; Gérard Friedlander; Fabiola Terzi
Journal:  Nat Med       Date:  2005-07-24       Impact factor: 53.440

Review 3.  ERBB receptors and cancer: the complexity of targeted inhibitors.

Authors:  Nancy E Hynes; Heidi A Lane
Journal:  Nat Rev Cancer       Date:  2005-05       Impact factor: 60.716

Review 4.  Untangling the ErbB signalling network.

Authors:  Y Yarden; M X Sliwkowski
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

5.  Effect of gender on the progression of nondiabetic renal disease: a meta-analysis.

Authors:  Joel Neugarten; Anjali Acharya; Sharon R Silbiger
Journal:  J Am Soc Nephrol       Date:  2000-02       Impact factor: 10.121

6.  Integrin alpha1beta1 controls reactive oxygen species synthesis by negatively regulating epidermal growth factor receptor-mediated Rac activation.

Authors:  Xiwu Chen; Tristin D Abair; Maria R Ibanez; Yan Su; Mark R Frey; Rebecca S Dise; D Brent Polk; Amar B Singh; Raymond C Harris; Roy Zent; Ambra Pozzi
Journal:  Mol Cell Biol       Date:  2007-03-05       Impact factor: 4.272

7.  Mineralocorticoid regulation of cyclooxygenase-2 expression in rat renal medulla.

Authors:  Ming-Zhi Zhang; Chuan-Ming Hao; Matthew D Breyer; Raymond C Harris; James A McKanna
Journal:  Am J Physiol Renal Physiol       Date:  2002-09

8.  Genetics of dark skin in mice.

Authors:  Karen R Fitch; Kelly A McGowan; Catherine D van Raamsdonk; Helmut Fuchs; Daekee Lee; Anne Puech; Yann Hérault; David W Threadgill; Martin Hrabé de Angelis; Gregory S Barsh
Journal:  Genes Dev       Date:  2003-01-15       Impact factor: 11.361

9.  Intrarenal dopamine attenuates deoxycorticosterone acetate/high salt-induced blood pressure elevation in part through activation of a medullary cyclooxygenase 2 pathway.

Authors:  Bing Yao; Raymond C Harris; Ming-Zhi Zhang
Journal:  Hypertension       Date:  2009-09-21       Impact factor: 10.190

10.  Clinical implication of metabolic syndrome on chronic kidney disease depends on gender and menopausal status: results from the Korean National Health and Nutrition Examination Survey.

Authors:  Mina Yu; Dong-Ryeol Ryu; Seung-Jung Kim; Kyu-Bok Choi; Duk-Hee Kang
Journal:  Nephrol Dial Transplant       Date:  2009-09-17       Impact factor: 5.992

View more
  9 in total

1.  Tubular MST1/2 Deletion and Renal Fibrosis.

Authors:  Monica Chang-Panesso
Journal:  J Am Soc Nephrol       Date:  2020-04-06       Impact factor: 10.121

2.  Amphiregulin Aggravates Glomerulonephritis via Recruitment and Activation of Myeloid Cells.

Authors:  Simon Melderis; Julia Hagenstein; Matthias Tobias Warkotsch; Julien Dang; Georg Rudolf Herrnstadt; Christoph Benjamin Niehus; Katrin Neumann; Ulf Panzer; Carmen Berasain; Matias A Avila; Pierre-Louis Tharaux; Gisa Tiegs; Oliver M Steinmetz
Journal:  J Am Soc Nephrol       Date:  2020-07-02       Impact factor: 10.121

Review 3.  The epidermal growth factor receptor axis and kidney fibrosis.

Authors:  Raymond C Harris
Journal:  Curr Opin Nephrol Hypertens       Date:  2021-05-01       Impact factor: 2.894

Review 4.  Modulation of Pathological Pain by Epidermal Growth Factor Receptor.

Authors:  Jazlyn P Borges; Katrina Mekhail; Gregory D Fairn; Costin N Antonescu; Benjamin E Steinberg
Journal:  Front Pharmacol       Date:  2021-05-12       Impact factor: 5.810

5.  Proximal tubular epithelial insulin receptor mediates high-fat diet-induced kidney injury.

Authors:  Hak Joo Lee; Meenalakshmi M Mariappan; Luke Norton; Terry Bakewell; Denis Feliers; Sae Byeol Oh; Andrew Donati; Cherubina S Rubannelsonkumar; Manjeri A Venkatachalam; Stephen E Harris; Isabelle Rubera; Michel Tauc; Goutam Ghosh Choudhury; C Ronald Kahn; Kumar Sharma; Ralph A DeFronzo; Balakuntalam S Kasinath
Journal:  JCI Insight       Date:  2021-02-08

6.  Revealing active components, action targets and molecular mechanism of Gandi capsule for treating diabetic nephropathy based on network pharmacology strategy.

Authors:  Qiqiang Zhang; Qing Ye; Xiaohui Huang; Ajing Xu; Yan Liu; Jia Qi; Hai Zhang; Jian Zhang
Journal:  BMC Complement Med Ther       Date:  2020-11-23

7.  Follistatin-Like-1 (FSTL1) Is a Fibroblast-Derived Growth Factor That Contributes to Progression of Chronic Kidney Disease.

Authors:  Nicholas A Maksimowski; Xuewen Song; Eun Hui Bae; Heather Reich; Rohan John; York Pei; James W Scholey
Journal:  Int J Mol Sci       Date:  2021-09-01       Impact factor: 5.923

8.  EGFR-mediated activation of adipose tissue macrophages promotes obesity and insulin resistance.

Authors:  Shirong Cao; Yu Pan; Jiaqi Tang; Andrew S Terker; Juan Pablo Arroyo Ornelas; Guan-Nan Jin; Yinqiu Wang; Aolei Niu; Xiaofeng Fan; Suwan Wang; Raymond C Harris; Ming-Zhi Zhang
Journal:  Nat Commun       Date:  2022-08-10       Impact factor: 17.694

9.  EGF receptor-mediated FUS phosphorylation promotes its nuclear translocation and fibrotic signaling.

Authors:  Manuel Chiusa; Wen Hu; Jozef Zienkiewicz; Xiwu Chen; Ming-Zhi Zhang; Raymond C Harris; Roberto M Vanacore; Jennifer A Bentz; Giuseppe Remuzzi; Ariela Benigni; Agnes B Fogo; Wentian Luo; Stavroula Mili; Matthew H Wilson; Roy Zent; Jacek Hawiger; Ambra Pozzi
Journal:  J Cell Biol       Date:  2020-09-07       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.